Dyadic International, Inc. DYAI

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
42/100
Developing

About Dyadic International, Inc.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and … Full DYAI analysis →

Competitive advantage assessment

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.79), suggesting sticky customer base.
  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.72), demonstrating pricing resilience across cycles.

Key risks

  • ROIC Below WACC or Peers ROIC at 28.1th percentile suggests inefficient capital deployment.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.31), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
38

Where DYAI ranks in Biotechnology

Dyadic International, Inc. ranks #347 of 713 scored companies in Biotechnology by moat score — the top 49%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near DYAI in Biotechnology
# Company Moat score Rating
343 Prelude Therapeutics Incorporat PRLD 42/100 Developing
344 Fate Therapeutics, Inc. FATE 42/100 Developing
345 ARS Pharmaceuticals, Inc. SPRY 42/100 Developing
346 Vera Therapeutics, Inc. VERA 42/100 Developing
347 Dyadic International, Inc. DYAI 42/100 Developing
348 MoonLake Immunotherapeutics MLTX 42/100 Developing
349 Pyxis Oncology, Inc. PYXS 42/100 Developing
350 Recursion Pharmaceuticals, Inc. RXRX 42/100 Developing
351 TScan Therapeutics, Inc. TCRX 41/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How DYAI scores on the Corporate Default defenses

Pricing Power

Score 38 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 43 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 61 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 17 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 53 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 42 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding DYAI's moat

What is Dyadic International, Inc.'s moat score?

Dyadic International, Inc. (DYAI) scores 42 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #347 of 713 scored companies in Biotechnology, the top 49%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Customer Stickiness (61/100) and its weakest is Capital Efficiency (17/100).

How does Dyadic International, Inc. compare with other Biotechnology companies?

Dyadic International, Inc. ranks #347 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Vera Therapeutics, Inc. (VERA) at 42 just above it and MoonLake Immunotherapeutics (MLTX) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Dyadic International, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Dyadic International, Inc.?

The Corporate Default template measures 6 defenses, and DYAI scores: Pricing Power (38), Cost Advantage (43), Customer Stickiness (61), Capital Efficiency (17), Resilience (53), Scale & Market Position (42). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000